PharmaCyte Biotech Inc (PMCB)

[Gmc2020]

I believe the timing of the diabetes presentation is both a function of being prepared to share the technology as well as a strategic fit.

Preparation takes a lot of time and Pmcb has been focused on pancreatic treatment and getting it to trial. The trail will also go along way to prove the efficacy of the diabetes treatment as the Magellan cells have already been proven, they just need the bio inert encapsulation.

For strategic purposes the timing is excellent. As we approach clinical trials potential buyers need to be aware of other applications of the technology to value it appropriately. Although the diabetes trial is likely not to commence anytime soon. It is very possible that the company who buys the pancreatic treatment or license will get it cheaper if they a free to finance future trials